Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes

Saul Blecker¹,²*, Hannah Park¹ and Stuart D. Katz²

Abstract

Background: Comorbid diabetes is common in heart failure and associated with increased hospitalization and mortality. Nonetheless, the association between glycemic control and outcomes among patients with heart failure and diabetes remains poorly characterized, particularly among low income and minority patients.

Methods: We performed a retrospective cohort study of outpatients with heart failure and diabetes in the New York City Health and Hospitals Corporation, the largest municipal health care system in the United States. Cox proportional hazard models were used to measure the association between HbA1c levels and outcomes of all-cause hospitalization, heart failure hospitalization, and mortality.

Results: Of 4723 patients with heart failure and diabetes, 42.6 % were black, 30.5 % were Hispanic/Latino, 31.4 % were Medicaid beneficiaries and 22.9 % were uninsured. As compared to patients with an HbA1c of 8.0–8.9 %, patients with an HbA1c of <6.5, 6.5–6.9, 7.0–7.9, and ≥9.0 % had an adjusted hazard ratio (aHR) (95 % CI) for all-cause hospitalization of 1.03 (0.90–1.17), 1.05 (0.91–1.22), 1.03 (0.90–1.17), and 1.13 (1.00–1.28), respectively. An HbA1c ≥ 9.0 % was also associated with an increased risk of heart failure hospitalization (aHR 1.33; 95 % CI 1.11–1.59) and a non-significant increased risk in mortality (aHR 1.20; 95 % CI 0.99–1.45) when compared to HbA1c of 8.0–8.9 %.

Conclusions: Among a cohort of primarily minority and low income patients with heart failure and diabetes, an increased risk of hospitalization was observed only for an HbA1c greater than 9 %.

Keywords: Heart failure, Diabetes, hbA1c

Background

Heart failure and diabetes are two chronic diseases that commonly coexist. Among patients with heart failure, the prevalence of diabetes is as high as 40 % [1–3] and is increasing [4]. The high rate of diabetes in heart failure holds clinical significance as diabetes has been associated with worse outcomes in heart failure. For instance, in a meta-analysis of 17 studies, patients with heart failure and diabetes were found to have a 28 % increase in mortality and a 36 % increase in hospitalizations as compared to patients with heart failure but no diabetes [5]. The relationship between heart failure and diabetes may be magnified among high-risk populations such as racial minorities, individuals of low socioeconomic status, and the uninsured [6–10].

Despite the increased risk of poor outcomes among patients with heart failure and diabetes, the optimal hemoglobin A1c (HbA1c) level for patients with heart failure and diabetes remains uncertain. Due to lack of existing data, heart failure guidelines do not specifically address the intensity of glycemic control among individuals with heart failure [11], and the American Diabetes Association (ADA) guidelines do not provide a specific treatment target [12]. Although elevated levels of HbA1c have been associated with increased risk for heart failure related hospitalizations [13–16], intervention trials in patients with Type 2 diabetes have failed to show benefit with tight glycemic control and some studies have even suggested harm [17–19]. Additionally, tight glycemic control could predispose to volume retention in heart
failure by decreasing the osmotic diuretic effect of glucose
sena [20]. Given the potential side effects of both tight
and loose glycemic control among heart failure patients,
moderate glycemic control would seem appropriate. In-
deed, a study of primarily male patients from Veterans
Affairs (VA) medical centers demonstrated a U-shaped
relationship between HbA1c and mortality, with the
lowest risk observed for patients with an HbA1c be-
tween 7.1 and 7.8 % [21]. Conversely, two studies from a
single academic advanced heart failure clinic found low
HbA1c values to be associated with increased risk of mortality, while a high HbA1c was associated with mortality for heart failure patients enrolled in the
CHARM study [24]. Notably, these prior studies focused
on select patient populations such as those who were
fully insured or who agreed to participate in a clinical
trial [21–24]. As a result, the optimal HbA1c target for
heart failure patients with diabetes remains uncertain,
especially for members of racial and ethnic minorities
not well represented in previous studies [21–24].

The purpose of this study was to evaluate the asso-
ciation of HbA1c with all-cause hospitalization among
patients with heart failure and diabetes in a hospital
system serving a diverse, urban, and primarily low-income
population. We hypothesized that hospitalization rates
would vary with level of HbA1c with a U-shaped relation-
ship, such that moderate glycemic control would be asso-
ciated with reduced all-cause hospitalization, heart failure
hospitalization, and mortality.

Methods

We performed a non-concurrent cohort study of pa-
tients in the New York City Health and Hospitals
Corporation (HHC), the largest municipal health care
system in the United States. The corporation serves
approximately 1.4 million people, of whom nearly
500,000 are uninsured, and includes 11 hospitals, six
diagnostic and treatment centers, four long term care
centers, and one hundred community health centers
[25]. The primary data source for the study was the
HHC data warehouse which contains data from the
electronic health records (EHRs) from each of the
hospitals and includes demographic information, clin-
ical measures, problem lists, laboratory tests and re-
sults, and medication orders. Patient data from HHC
was matched to two New York State data registries to
obtain outcomes data: the New York State Vital
Statistics and the New York Statewide Planning and
Research Cooperative System (SPARCS). Vital statis-
tics maintains records of deaths in the state, while
SPARCS contains all acute care admissions for non-
federal hospitals in the state.

We included patients with heart failure and diabetes
who had an outpatient clinic visit in HHC between 1/1/
2007 and 12/31/2010. Diagnoses were based on Inter-
national Classification of Diseases, Clinical Modify-
ation (ICD-9-CM) codes of 428 and 250, respectively, in the
problem list [3, 26]. Additional inclusion criteria were
age 18 years and older and measurement of an HbA1c
either on or up to 90 days prior to the clinic visit. For
patients with multiple encounters, we only included the
first visit for which inclusion criteria were met.

The primary outcome was all-cause hospitalization.
Secondary outcomes were heart failure hospitalization
and mortality. Heart failure hospitalization was based on
a principal diagnosis of heart failure using standard
ICD-9-CM codes [3, 27].

The primary exposure was HbA1c, which was catego-
rized into the following clinically relevant categories:
<6.5, 6.5–6.9, 7.0–7.9, 8.0–8.9, and ≥9.0 %. Other patient
characteristics included age, gender, race, ethnicity, pri-
mary payer, prior utilization, comorbidities, diabetes
severity, systolic blood pressure, pulse, creatinine,
hemoglobin, active medications, prior utilization, and
HHC facility of the clinic visit. Characteristics were
assessed at time of clinic visit with the exception of
lab values which, if unavailable at time of clinical
visit, could be included if assessed up to 90 days
prior to the clinic visit. In the data warehouse, race
was self-reported as a single category and included
responses of “Black or African American”, “Hispanic
Black”, and “Hispanic or Latino”. From this informa-
tion, we created a race variable that was categorized
as black or other and an ethnicity variable which was
categorized as Hispanic/Latino and other. Comorbid-
ities were based on standard algorithms [28]. Diabetes
severity was assessed using the diabetes complication
severity index, a validated index of complications of
diabetes that has been associated with hospitalization
and mortality [29]. Medication utilization was based on
an active prescription and included the following medication
classes: loop diuretic, angiotensin converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB),
beta blocker, insulin, metformin, and sulfonylurea. Prior
utilization included hospitalization in the prior 90 days
and number of hospitalizations, emergency department
visits, and clinic visits in the prior year.

Follow up time was defined from time of clinic visit.
Patients were followed to the time of death or December
31, 2010; patients who were unable to be accurately
matched to mortality data (n = 117) were censored on
their last date of service.

Statistical analysis

Differences in frequency of outcomes among all HbA1c
groups were compared using Pearson chi-squared tests.
We plotted Kaplan-Meier curves for hospitalization;
curves were compared using the log-rank test. Cox
proportional hazard models were developed to determine the relative association of HbA1c category with the primary outcome variable, all-cause hospitalization. The proportionality assumption was evaluated graphically using the -log(-log(survival function)) plot and statistically using the Schoenfeld residuals. We developed adjusted Cox models incorporating baseline patient characteristics as well as shared-frailty to account for clustering within each HHC site [30]. Covariates included in the adjusted model were age, sex, race, ethnicity, insurance, comorbidities, blood pressure, heart rate, creatinine, hemoglobin, medications, and prior utilization. Similar models were developed for the secondary outcomes. We performed a sensitivity analysis in which we developed similar models with the primary independent variable of HbA1c categorized as <6.5, 6.5–6.9, 7.0–7.9, 8.0–8.9, 9.0–9.9, 10.0–11.9, and ≥12.0 %.

Statistical significance was pre-specified with an alpha level of 0.05 (two-tailed). Statistical analyses were performed using Stata 13 (StataCorp, College Station, TX).

This study was approved by the New York University School of Medicine Institutional Review Board.

Results

Of the 4723 patients with heart failure and diabetes included in the study, the median age was 64 years, 42.6 % were black, and 30.5 % were Hispanic or Latino. At the time of clinic visit, 31.4 % of patients were Medicaid beneficiaries and 22.9 % of patients had no insurance.

The mean HbA1c (SD) for the cohort was 8.2 (2.4). The distribution of HbA1c categories of <6.5, 6.5–6.9, 7.0–7.9, 8.0–8.9, and ≥9.0 % was: 21.8, 12.7, 22.6, 15.0, and 28.0 %, respectively. Patients with high HbA1c were younger and had higher rates of Medicaid insurance when compared to patients with low HbA1c (Table 1). Patients in the lowest HbA1c group were most likely to be black and had the highest prevalence of kidney disease. Patients with higher HbA1c had higher rates of insulin use, while metformin was used most frequently among patients with HbA1c of 6.5–6.9 %. HbA1c appeared to be inversely correlated with number of outpatient encounters, as patients in the lowest two HbA1c groups had the highest average number of clinic visits (Table 1).

For the primary outcome of all-cause hospitalization, patients were followed for a median (25th, 75th percentile) of 173 (46,452) days. During follow up, 67.0 % of patients were hospitalized for any cause. Overall rates of hospitalization were similar across HbA1c groups (Table 2). Similarly, we found no difference in the Kaplan Meier curves between HbA1c groups (see Fig. 1). In unadjusted analysis, an HbA1c ≥9 % was associated with increased risk of hospitalization, while an HbA1c <6.5 % was associated with risk of hospitalization that did not reach statistical significance (Table 3). After adjusting for covariates, the lowest four categories of HbA1c (<6.5, 6.5–6.9, 7.0–7.9, and 8.0–8.9 %) were associated with similar hazard for hospitalization (Table 3). Only patients with an HbA1c ≥9.0 % had a significant increased risk for hospitalization (adjusted HR 1.13; 95 % CI 1.00–1.28) when compared to patients with HbA1c 8.0–8.9 % (Table 3).

The rate of heart failure hospitalizations was 35.3 % for patients with HbA1c ≥9.0 % and 26.6–28.9 % for patients in categories lower HbA1c (Table 2). After adjustment for covariates, HbA1c ≥9.0 % was associated with a hazard ratio for heart failure hospitalization of 1.33 (95 % CI 1.11–1.59) when compared to HbA1c 8.0–8.9 %. Other categories of HbA1c did not significantly differ in hazard ratio for heart failure hospitalization when compared to the reference (Table 3).

The median (25th, 75th percentile) follow up for mortality was 658 (289,1114) days. Over 30 % of patients with HbA1c <6.5 % died during the period while mortality rates for higher HbA1c categories ranged from 23.7 to 26.8 % (Table 2). In unadjusted analysis, HbA1c <6.5 % was associated with a 32 % (95 % CI 10–60 %) increase in hazard of death as compared to the reference group of HbA1c 8.0–8.9 %. However, this association was attenuated and was no longer significant after adjusting for covariates (adjusted HR 1.16; 95 % CI 0.94–1.42; Table 3). Similarly, an elevated HbA1c ≥9 % was associated with increased mortality in multivariable analysis that did not reach statistical significance (adjusted HR 1.20; 95 % CI 0.99–1.45; Table 3). Indeed, in multivariate adjustment, no level of HbA1c was statistically associated with increased mortality.

In sensitivity analysis in which we categorized higher HbA1c values into 9.0–9.9 %, 10.0–11.9 %, and ≥12 %, we found that hospitalization risk was similar for each of these individual categories as when grouped together (Appendix). An HbA1c over 12 % was associated with a significant increase in mortality as compared to HbA1c 8.0–8.9 %, with an adjusted HR 1.33 (95 % CI 1.03–1.73). We found no significant association between HbA1c of 9.0–9.9 % or 10.0–11.9 % and mortality (Appendix).

Discussion

In this cohort of patients with heart failure and diabetes from a diverse, urban, and primarily low-income hospital system, we found no difference in risk of hospitalization or mortality for HbA1c levels up to 8.9 %. Hospitalization risk only increased at the highest HbA1c level; an HbA1c of 9.0 % or higher was associated with a 13 % increase in the relative hazard of all-cause hospitalization and a 33 % increase in the relative hazard of heart failure hospitalization when compared to lower HbA1c.
Furthermore, we found the association between HbA1c and mortality to be significant only for HbA1c levels above 12%. These findings suggest that, in this patient population, glycemic control is not a strong predictor of outcomes in heart failure and diabetes and risk of hospitalization begins to increase only when HbA1c ≥ 9%.

Consistent with our initial hypothesis, that both high and low levels of HbA1c would be associated poor outcomes, we found that an HbA1c < 6.5% was associated

### Table 1: Baseline characteristics of 4,723 patients with heart failure and diabetes, by hemoglobin A1c (HbA1c) category

| HbA1c range | <6.5 | 6.5–6.9 | 7–7.9 | 8–8.9 | ≥9 |
|-------------|------|---------|-------|-------|----|
| (n = 1028)  | (n = 600) | (n = 1065) | (n = 706) | (n = 1324) |
| Age, years  | 67.1 (12.9) | 66.3 (12.4) | 65.4 (12.0) | 63.7 (11.7) | 60.9 (11.5) |
| Female      | 53.6 | 52.0 | 55.6 | 52.3 | 49.2 |
| Black Race  | 47.2 | 41.7 | 41.2 | 39.7 | 42.0 |
| Hispanic/Latino Ethnicity | 28.7 | 28.8 | 29.8 | 32.2 | 32.2 |
| Insurance   | Medicaid | 28.2 | 31.2 | 30.6 | 33.3 | 33.5 |
|             | Medicare | 30.5 | 27.0 | 25.7 | 24.1 | 18.7 |
|             | Private | 4.1 | 4.5 | 3.4 | 4.7 | 4.6 |
|             | Self-Pay | 18.0 | 18.8 | 22.4 | 24.9 | 27.7 |
|             | Other | 19.3 | 18.5 | 17.9 | 13.0 | 15.4 |
| Diabetes Severity Index | 3.5 (1.7) | 3.3 (1.7) | 3.3 (1.6) | 3.5 (1.7) | 3.4 (1.7) |
| Comorbid Conditions | Myocardial Infarction | 10.8 | 13.0 | 11.8 | 11.2 | 12.2 |
|             | Peripheral Vascular Disease | 14.7 | 11.7 | 13.3 | 15.0 | 11.7 |
|             | Cerebrovascular Disease | 17.8 | 15.5 | 16.9 | 13.2 | 10.7 |
|             | Dementia | 2.2 | 2.3 | 2.0 | 1.4 | 1.1 |
|             | Chronic Pulmonary Disease | 23.8 | 26.3 | 27.2 | 24.5 | 25.8 |
|             | Rheumatic Disease | 2.4 | 1.8 | 2.0 | 1.1 | 1.4 |
|             | Liver Disease | 7.5 | 5.2 | 4.0 | 3.7 | 4.8 |
|             | Renal Disease | 30.3 | 19.7 | 18.6 | 21.1 | 21.4 |
|             | Malignancy or Tumor | 8.6 | 10.0 | 6.4 | 6.5 | 5.8 |
| Heart Rate, beats/min | 74.8 (13.1) | 75.2 (12.9) | 76.3 (13.2) | 77.6 (14.1) | 78.2 (13.8) |
| Systolic Blood Pressure, mmHG | 133.7 (22.4) | 135.3 (23.0) | 134.6 (22.2) | 135.6 (23.4) | 134.7 (22.9) |
| Creatinine, mg/dl | 1.9 (1.8) | 1.5 (1.2) | 1.5 (1.2) | 1.5 (1.3) | 1.5 (1.3) |
| Hemoglobin, g/dl | 11.6 (2.0) | 12.0 (1.9) | 12.0 (1.9) | 12.1 (1.9) | 12.2 (2.0) |
| ACE inhibitor or ARB | 55.1 | 58.2 | 58.8 | 56.7 | 59.9 |
| Beta-Blocker | 36.7 | 34.8 | 37.5 | 35.6 | 34.5 |
| Loop Diuretic | 57.9 | 63.0 | 62.4 | 62.3 | 57.4 |
| Insulin | 21.7 | 25.2 | 35.8 | 50.9 | 62.3 |
| Metformin | 14.1 | 22.2 | 16.4 | 18.8 | 19.5 |
| Sulfonylurea | 9.0 | 11.7 | 12.4 | 9.8 | 10.6 |
| Prior Utilization | Hospitalization in Prior 90 Days | 54.3 | 45.3 | 52.8 | 53.8 | 58.9 |
| | Hospitalizations, Prior Year | 1.5 (2.0) | 1.2 (1.8) | 1.4 (1.9) | 1.4 (1.7) | 1.5 (2.0) |
| | ED Visits, Prior Year | 0.6 (1.3) | 0.5 (1.1) | 0.6 (1.7) | 0.5 (1.3) | 0.6 (1.3) |
| | Clinic Visits, Prior Year | 6.9 (12.8) | 7.3 (15.3) | 6.6 (15.0) | 5.3 (12.6) | 5.5 (12.2) |

Values are percentages or mean (standard deviation)
with increased risk of mortality and a nonsignificant increase in hospitalization in unadjusted analysis. However, a low HbA1c was also associated with a number of factors associated with poor outcomes, including increased age, cerebrovascular disease, and creatinine. After adjusting for such confounders, a low HbA1c was no longer associated with mortality or hospitalization. Some studies have found that HbA1c may have a U- or J-shaped relationship to outcomes [21, 31, 32], suggesting there may also be a low threshold, below which risk increases [32]. In this population of patients with heart failure and diabetes, any risk associated with low HbA1c was explained by other factors. These findings do not support a low threshold effect in patients with heart failure and diabetes.

In our study, only levels of HbA1c of 9 % or higher were associated with hospitalization and mortality. Conversely, observational studies in the general population have suggested that tight glycemic control was associated with increased mortality [22, 23]. Conversely, among a subgroup of patients with heart failure and diabetes enrolled in the CHARM study, Gerstein and colleagues found that a 1 % increase in HbA1c was associated with an increased hazard ratio of 1.13 for heart failure hospitalization and 1.11 for mortality [24]. Finally, Aguilar and colleagues studied 5815 male patients in the VA and found that an HbA1c of 7.1 – 7.8 % was associated with a hazard ratio for mortality of 1.31 – 1.45 as compared to both higher and lower values. However, the authors found no significant association between HbA1c and hospitalization [21].

While the studies by Gerstein [24] and Aguilar [21] found higher HbA1c was associated with increased risk of mortality, we found no statistical association between HbA1c and health outcomes among patients with heart failure and diabetes have been mixed. Two studies of patients with advanced heart failure from the same single center suggested that tighter glycemic control was associated with increased mortality [22, 23]. Conversely, among a subgroup of patients with heart failure and diabetes enrolled in the CHARM study, Gerstein and colleagues found that a 1 % increase in HbA1c was associated with an increased hazard ratio of 1.13 for heart failure hospitalization and 1.11 for mortality [24]. Finally, Aguilar and colleagues studied 5815 male patients in the VA and found that an HbA1c of 7.1 – 7.8 % was associated with a hazard ratio for mortality of 1.31 – 1.45 as compared to both higher and lower values. However, the authors found no significant association between HbA1c and hospitalization [21].

While the studies by Gerstein [24] and Aguilar [21] found higher HbA1c was associated with increased risk of mortality, we found no statistical association between HbA1c and mortality in our primary analysis. The difference between our study and the prior studies is that we included a real-world patient population

| HbA1c range | Hospitalization (n=1028) | <6.5 | 6.5–6.9 (n=600) | 7–7.9 (n=1065) | 8–8.9 (n=706) | ≥9 (n=1324) | P |
|-------------|-------------------------|------|----------------|----------------|--------------|-------------|---|
| Hospitalization | 68.6 | 64.7 | 65.2 | 66.2 | 68.9 | 0.16 |
| Heart Failure Hospitalization | 26.6 | 27.5 | 28.9 | 28.8 | 35.3 | <0.001 |
| Mortality | 30.5 | 25.5 | 24.1 | 23.7 | 26.8 | <0.01 |

Fig. 1 Kaplan Meier curves for hospitalization free survival by HbA1c category among 4723 patients with heart failure and diabetes. p = 0.10 for differences among curves using the log-rank test.
HbA1c has been shown to ≥ 9%, and lower HbA1c for subpopulations such as those known to have higher levels of HbA1c as compared to white patients [35, 37], HbA1c has been shown to have a similar relationship for clinical outcomes among different racial groups [36, 38] and the same target HbA1c has been recommended for all patients with diabetes, regardless of race [12].

Our findings should be interpreted in the context of study limitations. First, inclusion was based on diagnostic coding algorithms and may be subject to misclassification despite using validated diagnostic codes [39, 40]. Second, although the HHC database contains extensive data on vital signs, inpatient and outpatient claims, medication utilization and laboratory data, it may lack data on several potentially important variables, including ejection fraction and functional status. As a result, we were unable to determine of HbA1c had a differential association with outcomes for patients with heart failure with reduced versus preserved ejection fraction or patients with type 1 versus type 2 diabetes. Third, as we relied on real world EHR data, some of our data may be subject to misclassification, such as self-reported race field. Fourth, the data relied on the EHR within a single hospital system so we may have missed medication prescriptions and clinical encounters that occurred at another facility. Fifth, as we relied on a state registry for hospitalization information, we may have missed some hospitalizations that occurred out of state. Sixth, the median follow up for mortality was 658 days. Nonetheless, as the mortality rate was over 25% in this study, the null finding of association between HbA1c and mortality was probably not fully attributable to low event rate.

Our study had a number of unique strengths. We included patients from a large public health system which serves many uninsured and minority patients in real world practice settings. Such patients are frequently underrepresented in clinical trials [41]. Additionally, we linked our EHR data to state registry data to obtain complete hospitalization follow up. This is notable as a large number heart failure related hospitalizations are hospitals other than where care is primarily obtained [42].

Conclusions
We found the associated risk of hospitalization increases for HbA1c ≥ 9%, and not lower HbA1c values, among patients with heart failure and diabetes. The ADA currently recommends targeting an HbA1c < 7% for most patients with diabetes but suggests that “less stringent A1c goals (such as < 8%) may be appropriate” for subpopulations such as those with limited life expectancy or significant comorbidity [12]. In support of less stringent glycemic target for patients with heart failure and diabetes, our data suggest that there may be a weak threshold effect of HbA1c above 9% in this population. Nonetheless, randomized control trials are needed to determine the recommended HbA1c for patients with heart failure and diabetes, who are at high risk of hospitalization and mortality.

Ethics approval and consent to participate
This study was approved by the NYU School of Medicine institutional review board, which granted a waiver of consent.

Consent for publication
Not applicable.

Availability of data and materials
Data will not be shared due to restrictions related to patient confidentiality.

Table 3 Hazard ratio for outcomes of hospitalization, mortality, and heart failure hospitalization by HbA1c category among 4723 patients with heart failure and diabetes. Adjusted for age, sex, race, ethnicity, insurance, comorbidities, blood pressure, heart rate, creatinine, hemoglobin, medications, and prior utilization

| HbA1c category | Hospitalization Unadjusted | Heart failure hospitalization Unadjusted | Mortality Unadjusted |
|---------------|----------------------------|----------------------------------------|---------------------|
| <6.5          | 1.12 (0.99–1.26)           | 0.95 (0.79–1.14)                       | 1.32 (1.10–1.60)    |
| 6.5–6.9       | 1.06 (0.93–1.22)           | 0.97 (0.79–1.20)                       | 1.09 (0.87–1.35)    |
| 7–7.9         | 1.04 (0.93–1.18)           | 1.07 (0.89–1.28)                       | 1.03 (0.85–1.25)    |
| 8–8.9         | 1 [ref]                    | 1 [ref]                                | 1 [ref]             |
| ≥9            | 1.15 (1.03–1.29)           | 1.13 (1.00–1.28)                       | 1.13 (0.94–1.36)    |

Unadjusted Adjusted

| HbA1c category | Hospitalization | Heart failure hospitalization | Mortality |
|---------------|----------------|------------------------------|-----------|
| <6.5          | 1.13 (1.11–1.55) | 1.31 (1.11–1.59) | 1.13 (0.94–1.36) |
| 6.5–6.9       | 1.13 (1.00–1.28) | 1.33 (1.11–1.59) | 1.20 (0.99–1.45) |
| 7–7.9         | 1.13 (1.00–1.28) | 1.33 (1.11–1.59) | 1.20 (0.99–1.45) |
| 8–8.9         | 1 [ref]          | 1 [ref]                    | 1 [ref]    |
| ≥9            | 1.13 (1.00–1.28) | 1.33 (1.11–1.59) | 1.20 (0.99–1.45) |
Appendix

Table 4 Hazard ratio for outcomes using further stratification of HbA1c values. Adjusted for age, sex, race, ethnicity, insurance, comorbidities, blood pressure, heart rate, creatinine, hemoglobin, medications, and prior utilization

| HbA1c Category | Hospitalization Unadjusted | Heart Failure hospitalization Unadjusted | Heart Failure hospitalization Adjusted | Mortality Unadjusted | Mortality Adjusted |
|---------------|---------------------------|----------------------------------------|--------------------------------------|---------------------|-------------------|
|               |                           |                                        |                                      |                     |                   |
| <6.5          | 1.12 (0.99–1.26)          | 0.95 (0.79–1.14)                       | 1.09 (0.87–1.35)                    | 1.16 (0.94–1.42)    |
| 6.5–6.9       | 1.06 (0.93–1.22)          | 0.97 (0.79–1.20)                       | 1.03 (0.83–1.29)                    | 1.11 (0.88–1.41)    |
| 7–7.9         | 1.04 (0.93–1.18)          | 1.07 (0.89–1.28)                       | 1.12 (0.93–1.36)                    | 1.08 (0.88–1.33)    |
| 8–8.9         | 1 [<ref>]                 | 1 [<ref>]                              | 1 [<ref>]                           | 1 [<ref>]           |
| 9–9.9         | 1.14 (0.99–1.32)          | 1.23 (0.99–1.52)                       | 1.22 (0.98–1.53)                    | 1.14 (0.90–1.44)    |
| 10–11.9       | 1.15 (1.00–1.33)          | 1.27 (1.03–1.57)                       | 1.39 (1.12–1.73)                    | 1.16 (0.91–1.48)    |
| ≥12           | 1.16 (0.99–1.36)          | 1.47 (1.18–1.82)                       | 1.38 (1.09–1.74)                    | 1.22 (0.95–1.56)    |

Abbreviations
HbA1c: hemoglobin A1c; ADA: American Diabetes Association; VA: Veterans Affairs; HHC: New York City Health and Hospitals Corporation; ICD-9-CM: International Classification of Diseases, Clinical Modification; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; HR: hazard ratio; CI: confidence interval; EHR: electronic health record.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SB led the study conception and design, participated in analysis of data, and drafted the manuscript. HP performed the statistical analysis. SK participated in conception and design and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements
We thank Yan Rosentsveyg, Frank Chimkin, and Lisa Elkind at the New York City Health and Hospitals Corporation for their assistance with obtaining the data used in this study and Margaret Paul, MS for assistance with data cleaning.

Funding
This work was supported by the National Center for Advancing Translational Sciences (NCATS) grant KL2 TR000053 and the Agency for Healthcare Research and Quality (AHRQ) K08 HS23683.

Received: 29 October 2015 Accepted: 12 May 2016
Published online: 20 May 2016

References
1. Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209-16.
2. Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;154(2):277, e1-8.
3. Blecker S, Paul M, Täskä G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61(12):1259-67.
4. From AM, Leibson CL, Buris F, Redfield MM, Weston SA, Jacobsen SJ, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119(7):591-9.
5. Kamakshi M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. J Card Fail. 2009;15(4):305-9.
6. Bahrami H, Krommal R, Bluemke DA, Olson J, Shea S, Liu K, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168(19):2386-45.
7. Foraker RE, Rose KM, Suchindran CM, Chang PP, McNeill AM, Rosamond WD. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004). Circ Heart Fail. 2011;4(3):308-16.
8. Link CL, McKinlay JB. Disparities in the prevalence of diabetes: is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis. 2009;19(3):288-92.
9. Robbins JM, Vaccarino V, Zhang H, Kasl SV. Socioeconomic status and type 2 diabetes in African American and non-Hispanic white women and men: evidence from the Third National Health and Nutrition Examination Survey. Am J Public Health. 2001;91(1):76-83.
10. Winkleby MA, Kraemer HC, Afn DK, Varady AN. Ethnic and socioeconomic differences in cardiovascular disease risk factors: findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA. 1998;280(4):356-62.
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.
12. American DA. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37 Suppl 1:S14-80.
13. Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of hemoglobin A1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. 2010;59(8):2020-6.
14. Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, et al. Hba1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008;51(1):2197–204.
15. Romero SP, García-Egido A, Escobar MA, Andrey JL, Corzo R, Perez V, et al. Impact of new-onset diabetes mellitus and glycemic control on the prognosis of heart failure patients: a propensity-matched study in the community. Int J Cardiol. 2012;167:1206.
16. van Melle JP, Bot M, de Jonge P, de Boer PA, van Veldhuisen DJ, Woolsey MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33(3):2084-9.
17. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
38. Tsugawa Y, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? A cross-sectional study. Ann Intern Med. 2012;157(3):153-9.

39. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43(5):480-5.

40. Goff Jr DC, Pandey DK, Chan FA, Ortiz C, Nichaman MZ. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med. 2000;160(2):197-202.

41. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162(15):1682-8.

42. Nasir K, Lin Z, Bueno H, Normand SL, Dyee EE, Keenan PS, et al. Is same-hospital readmission rate a good surrogate for all-hospital readmission rate? Med Care. 2010;48(5):477-81.